Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

NCT03024216 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer Metastatic

Interventions

DRUG: Atezolizumab1200 mg IV
DRUG: Sipuleucel-T

Sponsor

University of Hawaii

Collaborators

[object Object]
[object Object]